Myasthenia Gravis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, Others), By End Use (Hospitals & Clinics, Ambulatory Surgical Centers, Others), Region and Competition, 2020-2030F

Market Overview

The Global Myasthenia Gravis Treatment Market, valued at USD 2.32 Billion in 2024, is projected to experience a CAGR of 7.44% to reach USD 3.57 Billion by 2030. Myasthenia Gravis treatment encompasses pharmaceutical interventions designed to manage this chronic autoimmune neuromuscular disorder, characterized by varying degrees of skeletal muscle weakness and fatigue resulting from impaired nerve-muscle communication. Market growth is primarily driven by the increasing prevalence of the condition globally and enhanced diagnostic capabilities that lead to earlier detection. Furthermore, advancements in therapeutic modalities, including the development of novel immunotherapies and biologics, significantly contribute to expanding treatment options and patient access.

A significant challenge impeding market expansion is the substantial cost associated with advanced therapies, particularly biologics. According to the American Academy of Neurology, in 2021, the total prevalence of myasthenia gravis in the United States was estimated at 37.0 per 100,000 individuals, with an overall incidence of 3.2 new cases per 100,000 individuals. These high treatment expenditures can limit patient access and adoption, particularly in regions with underdeveloped healthcare infrastructure or restrictive reimbursement policies.

Key Market Drivers

Rising global prevalence of Myasthenia Gravis significantly fuels the demand for effective treatments. The increasing number of diagnosed cases worldwide broadens the patient pool requiring chronic disease management, necessitating a wider array of therapeutic options and greater accessibility to existing ones. This trend is driven by improved diagnostic capabilities and enhanced disease awareness among healthcare professionals. For instance, according to a systematic review published in Neuroepidemiology, in October 2024, the mean prevalence rate of Myasthenia Gravis increased from 97.5 cases per million person-years during 1967-2007 to 220.1 cases per million person-years in the 2008-2022 timeframe. This substantial rise in prevalence directly translates into an expanded market for Myasthenia Gravis therapies globally.

Advancements in therapeutic modalities represent another pivotal driver, reshaping the treatment landscape with more targeted and efficacious interventions. Continuous research and development efforts have yielded novel drugs that specifically address the underlying immunological mechanisms, moving beyond traditional broad-spectrum immunosuppressants. These innovations offer improved outcomes and reduced side effects, enhancing treatment adherence and patient quality of life. According to AJMC, in January 2024, the FDA approved two new drugs in 2023 to treat myasthenia gravis: rozanolixizumab-noli (Rystiggo) for both anti–acetylcholine receptor and anti–muscle-specific kinase antibody-positive MG, and zilucoplan (Zilbrysq) for self-administration by daily injection. Such approvals expand available options and stimulate further investment. The robust developmental environment is further indicated by a cross-sectional study on ClinicalTrials. gov, published in January 2024, which identified 62 registered trials focusing on novel therapies for myasthenia gravis from 2007 to 2023, demonstrating a consistent yearly rise in new trial initiations.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with advanced therapies, particularly biologics, presents a significant impediment to the growth of the Global Myasthenia Gravis Treatment Market. These high expenditures directly constrain patient access and adoption, especially in regions with developing healthcare infrastructure or stringent reimbursement policies. Healthcare systems and individual patients often struggle to absorb the ongoing financial burden of these advanced treatments, leading to delays in initiation or discontinuation of therapy.

This challenge is further underscored by data indicating limited access to innovative medicines. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2024, only 46% of centrally approved innovative medicines, including orphan medicines, were available to patients across 27 EU member states. Moreover, only 29% of these medicines were fully available through public reimbursement in 2024. Such restrictions on availability and reimbursement directly translate into reduced market penetration for novel Myasthenia Gravis therapies, despite their therapeutic advancements. When treatments are not readily accessible or affordable, the overall market expansion is hindered as patient uptake remains low, irrespective of the medical efficacy of the therapeutic options.

Key Market Trends

The global Myasthenia Gravis treatment market is significantly influenced by the expansion of personalized medicine approaches. This trend emphasizes tailoring treatments to individual patient profiles, moving beyond a one-size-fits-all strategy to improve efficacy and minimize adverse effects. The increasing understanding of disease heterogeneity and the identification of specific biomarkers are crucial to this evolution. According to the Pharmaceutical Research and Manufacturers of America (PhRMA) 2024 Special 301 Submission, PhRMA member companies invested nearly $101 billion in research and development (R&D) in 2022 alone, underscoring the extensive financial commitment towards innovative and personalized therapeutic solutions. Ongoing efforts to identify precise indicators for treatment response are evident, as a review of biomarkers used in clinical trials, published in Clinical Immunology in July 2025, tracked 33 distinct biomarkers, including acetylcholine receptor (AChR) antibodies, IgG, and IL-2, most frequently reported for Myasthenia Gravis treatments.

Another pivotal trend shaping the market is the increased adoption of subcutaneous drug delivery methods. This shift offers substantial benefits such as enhanced patient convenience, improved adherence through self-administration, and a potential reduction in healthcare resource utilization. These delivery advancements enable patients to receive treatment outside traditional clinical settings, fostering greater independence. Reflecting the industry's focus on innovative administration routes, the PhRMA Foundation's 2023 Annual Report indicated that "Drug Delivery" research accounted for 16.5% of its awarded grants, highlighting continuous investment in this area. A notable development demonstrating this trend was Argenx's announcement of the U. S. Food and Drug Administration approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous use in generalized Myasthenia Gravis on June 20, 2023, marking the first subcutaneous treatment option for this condition.

Segmental Insights

The Hospitals & Clinics segment is experiencing rapid growth in the Global Myasthenia Gravis Treatment Market due to its pivotal role in providing comprehensive patient care. This segment offers a broad spectrum of diagnostic tools, including advanced antibody tests, crucial for precise and timely diagnosis of myasthenia gravis. Furthermore, hospitals are equipped to deliver multidisciplinary treatment approaches, essential for managing the complex and varied presentations of the disease. The capacity of these facilities to handle severe myasthenic crises, which often necessitate intensive care and specialized interventions, significantly drives patient admissions and treatment demand. Enhanced investment in state-of-the-art healthcare infrastructure also contributes to the expansion of this segment, ensuring access to a wide array of specialized services for a growing patient population.

Regional Insights

North America leads the global myasthenia gravis treatment market due to its advanced healthcare infrastructure and high awareness of the disease. The region benefits from a significant prevalence of myasthenia gravis cases, driving substantial investment in research and development by pharmaceutical companies. Furthermore, a favorable regulatory environment, notably the consistent approval of novel therapies by the U. S. Food and Drug Administration (FDA), accelerates the introduction and adoption of advanced treatments, including monoclonal antibodies and targeted therapies. This combination of strong patient demographics, robust healthcare expenditure, and proactive regulatory support solidifies North America's dominant market position.

Recent Developments

• In August 2025, argenx announced positive Phase III data for its FcRn inhibitor, Vyvgart (efgartigimod), in generalized myasthenia gravis (gMG) patients who are seronegative for acetylcholine receptor (AChR) antibodies. The ADAPT SERON trial demonstrated statistically significant and clinically meaningful improvement in disease activity for this specific subpopulation. These results are expected to support a supplemental application to expand Vyvgart's label, potentially making it the FcRn inhibitor with the broadest indication in gMG, encompassing MuSK-positive, LRP4-positive, and triple seronegative patients, thereby reaching additional individuals in the Global Myasthenia Gravis Treatment Market.

• In April 2025, Johnson & Johnson received U.S. FDA approval for IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adults and adolescents aged 12 years and older. This new FcRn-blocking monoclonal antibody is indicated for patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive. The approval marks a significant advancement by providing a long-lasting treatment option that addresses the underlying cause of the disease in a broad population of individuals with gMG. It represents a new therapeutic option for managing the severe muscle weakness and fatigue characteristic of this condition.

• In April 2025, Cartesian Therapeutics, Inc. reported 12-month efficacy and safety results from its Phase IIb trial of Descartes-08, an mRNA cell therapy candidate for generalized myasthenia gravis (MG). The data demonstrated sustained improvement in MG symptoms for patients who received a single six-week treatment course of Descartes-08, with benefits persisting through the 12-month follow-up. This double-blind, placebo-controlled, crossover trial involved heavily pre-treated, symptomatic patients, highlighting the potential of this innovative cell therapy to offer durable responses in the Global Myasthenia Gravis Treatment Market.

• In August 2024, Merck initiated the Phase III MyClad trial, dosing the first patient to evaluate the efficacy and safety of oral cladribine for generalized Myasthenia Gravis (gMG). This pivotal study positions cladribine capsules as a potential pioneering oral treatment option in the Global Myasthenia Gravis Treatment Market. The therapy is designed to selectively target B and T lymphocytes, which are believed to be instrumental in producing autoantibodies that contribute to inflammation at neuromuscular junctions. This approach aims to address the underlying cause of gMG with the added convenience of an oral administration.

Key Market Players

• Alexion Pharmaceutical Inc.
• Grifols International, S.A.
• Avadel Pharmaceuticals, Plc.
• Novartis AG
• Pfizer, Inc.
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc.
• Bausch Health Companies Inc.

Report Scope:

In this report, the Global Myasthenia Gravis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Myasthenia Gravis Treatment Market, By Treatment Type:

o   CholinesteraseInhibitors

o   Chronic Immunomodulators

o   Monoclonal Antibodies

o   Rapid Immunotherapies

o   Thymectomy

o   Others

• Myasthenia Gravis Treatment Market, By End use:

o   Hospitals & Clinics

o   Ambulatory Surgical Centers

o   Others

• Myasthenia Gravis Treatment Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Myasthenia Gravis Treatment Market.

Available Customizations:

Global Myasthenia Gravis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Myasthenia Gravis Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]